Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting

T cells in the bone marrow from patients with acute myeloid leukemia have increased expression of several immune checkpoint molecules. Can this knowledge be translated to novel therapeutic strategies?